ACADIA Pharmaceuticals (0A4W) Share Forecast & Price Target
0A4W Analyst Ratings
Moderate Buy
10Buy5Hold0Sell
Based on 15 analysts giving stock ratings to ACADIA Pharmaceuticals in the past 3 months
0A4W Stock 12 Month Forecast
Average Price Target
$31.43▲(16.97% Upside)Based on 15 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $31.43 with a high forecast of $37.00 and a low forecast of $23.00. The average price target represents a 16.97% change from the last price of $26.87.
Past 12 Months12 Month ForecastDec2025Sep2026
High$37.00
Average$31.43
Low$23.00
Highest Price TargetHighest$37.00Average Price Target$31.43Lowest Price TargetLowest$23.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | Needham | $35 | buy | 30.26%Upside | Reiterated | 10/19/26 | ||
| Ashwani Verma | UBS | $49→$23 | hold | -14.40%Downside | Downgraded | 10/14/26 | ||
| Malcolm Hoffman | BMO Capital | $34 | buy | 26.54%Upside | Reiterated | 10/12/26 | ||
| Tazeen Ahmad | Bank of America Securities | $31 | buy | 15.37%Upside | Reiterated | 10/09/26 | ||
| Brian Abrahams | RBC Capital | $37→$36 | buy | 33.98%Upside | Reiterated | 10/08/26 | ||
| Yigal Nochomovitz | Citi | $40→$33 | buy | 22.81%Upside | Reiterated | 09/25/26 | ||
| Jason Butler | Citizens JMP | $36→$33 | buy | 22.81%Upside | Reiterated | 09/25/26 | ||
| Sumant Kulkarni | Canaccord Genuity | $36 | buy | 33.98%Upside | Reiterated | 09/25/26 | ||
| David Hoang | Deutsche Bank | $38→$31 | buy | 15.37%Upside | Reiterated | 09/25/26 | ||
| Ananda Ghosh | H.C. Wainwright | $37→$33 | buy | 22.81%Upside | Reiterated | 09/25/26 | ||
| Sean Laaman | Morgan Stanley | $27→$28 | hold | 4.21%Upside | Assigned | 08/25/26 | ||
| Ritu Baral | TD Cowen | $37 | buy | 37.70%Upside | Assigned | 08/05/26 | ||
| Paul Matteis | Stifel Nicolaus | $25 | hold | -6.96%Downside | Reiterated | 08/05/26 | ||
| Matthew Hershenhorn | Oppenheimer | $23→$25 | hold | -6.96%Downside | Reiterated | 08/05/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 08/04/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | 10/19/26 | $35 | buy | 30.26%Upside | Reiterated | Needham | ||
| Ashwani Verma | 10/14/26 | $49→$23 | hold | -14.40%Downside | Downgraded | UBS | ||
| Malcolm Hoffman | 10/12/26 | $34 | buy | 26.54%Upside | Reiterated | BMO Capital | ||
| Tazeen Ahmad | 10/09/26 | $31 | buy | 15.37%Upside | Reiterated | Bank of America Securities | ||
| Brian Abrahams | 10/08/26 | $37→$36 | buy | 33.98%Upside | Reiterated | RBC Capital | ||
| Yigal Nochomovitz | 09/25/26 | $40→$33 | buy | 22.81%Upside | Reiterated | Citi | ||
| Jason Butler | 09/25/26 | $36→$33 | buy | 22.81%Upside | Reiterated | Citizens JMP | ||
| Sumant Kulkarni | 09/25/26 | $36 | buy | 33.98%Upside | Reiterated | Canaccord Genuity | ||
| David Hoang | 09/25/26 | $38→$31 | buy | 15.37%Upside | Reiterated | Deutsche Bank | ||
| Ananda Ghosh | 09/25/26 | $37→$33 | buy | 22.81%Upside | Reiterated | H.C. Wainwright | ||
| Sean Laaman | 08/25/26 | $27→$28 | hold | 4.21%Upside | Assigned | Morgan Stanley | ||
| Ritu Baral | 08/05/26 | $37 | buy | 37.70%Upside | Assigned | TD Cowen | ||
| Paul Matteis | 08/05/26 | $25 | hold | -6.96%Downside | Reiterated | Stifel Nicolaus | ||
| Matthew Hershenhorn | 08/05/26 | $23→$25 | hold | -6.96%Downside | Reiterated | Oppenheimer | ||
| Unknown AnalystNot Ranked | 08/04/26 | ― | hold | ― | Reiterated | Guggenheim |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering ACADIA Pharmaceuticals
3 Months
Success Rate9/13 ratings generated profit
69%
Average Return
+8.76%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.76% per trade.
1 Year
Success Rate16/29 ratings generated profit
55%
Average Return
+7.27%
Copying Jason Butler's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +7.27% per trade.
2 Years
Success Rate6/13 ratings generated profit
46%
Average Return
+5.19%
Copying Tessa Romero's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of +5.19% per trade.
0A4W Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 1 | 7 | 12 |
| Buy | 13 | 16 | 29 | 26 | 20 |
| Hold | 4 | 6 | 9 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 23 | 28 | 39 | 42 | 40 |
In the current month, 0A4W has received 32 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 0A4W average Analyst price target in the past 3 months is 31.43.
0A4W Financial Forecast
High$0.29
Consensus$0.20
Low$0.11
0A4W Earnings Forecast
Next quarter’s earnings estimate for 0A4W is $0.20 with a range of $0.11 to $0.29. The previous quarter’s EPS was $0.18. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$339M
Consensus$333M
Low$325M
0A4W Sales Forecast
Next quarter’s sales forecast for 0A4W is $332.58M with a range of $325.00M to $338.63M. The previous quarter’s sales results were $307.96M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0A4W Stock Forecast FAQ
What is GB:0A4W’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is $31.43.
What is GB:0A4W’s upside potential, based on the analysts’ average price target?
ACADIA Pharmaceuticals has 16.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACADIA Pharmaceuticals a Buy, Sell or Hold?
ACADIA Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 5 hold ratings and 0 sell ratings.
What is ACADIA Pharmaceuticals’s share price target?
The average share price target for ACADIA Pharmaceuticals is $31.43. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $37.00, and the lowest forecast is $23.00. The average share price target represents a 16.97% increase from the current price of $26.87.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of ACADIA Pharmaceuticals?
To buy shares of GB:0A4W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
